Abstract
Background Monoclonal antibodies with high efficiency and specificity are one of the best strategies to diagnose and treat a variety of diseases such as cancer, autoimmunity, and inflammatory diseases. The market for monoclonal therapeutic antibodies (MTAs) has grown dramatically in the past decade. Objective Given the importance of these issues, developing countries spend a high cost on importing or producing MTAs annually. This study intends to examine the market of monoclonal therapeutic antibodies in Iran and predict the future growth rate of this market using the obtained data. Methods Data on the status of MTAs in the country (from 2008 to 2018) were obtained from the Food and Drug Deputy of Mazandaran University of Medical Sciences. The market status of MTAs was studied based on the dosage forms, application, and price. Then, the market outlook was predicted up to year 2025. Results The results showed that 58.8% of all MTAs were humanized, and 86% of all antibody-based drugs were used to treat cancer. Sales of MTA-based medications will reach $454 million by 2025 and are projected to grow significantly in the future. Conclusion Given the increasing technology of the production of MTAs and their use in targeted therapies worldwide, their consumption market in Iran is expected to grow significantly.
Highlights
Antibodies are glycoproteins that are produced by B lymphocytes in response to antigens, bind to antigens, and play an important role in immune defense (Figure 1(a)) [1]
An increase in the discovery and production of Monoclonal antibodies (mAbs) and an increase in our understanding of diseases at the molecular level, as well as a targeted treatment approach for many chronic diseases by physicians, have led to the increasing use of MTAs worldwide. is study intends to examine the market of monoclonal therapeutic antibodies in Iran and predict the future growth rate of this market using the obtained data
17 FDA-approved types of MTAs have been sold during the study period in Iran
Summary
Antibodies are glycoproteins that are produced by B lymphocytes in response to antigens, bind to antigens, and play an important role in immune defense (Figure 1(a)) [1]. Monoclonal antibodies (mAbs) are produced by a B-cell clone against only one antigenic epitope. Monoclonal antibodies with high efficiency and specificity are one of the best strategies to diagnose and treat a variety of diseases such as cancer, autoimmunity, and inflammatory diseases. E market for monoclonal therapeutic antibodies (MTAs) has grown dramatically in the past decade. Is study intends to examine the market of monoclonal therapeutic antibodies in Iran and predict the future growth rate of this market using the obtained data. E results showed that 58.8% of all MTAs were humanized, and 86% of all antibody-based drugs were used to treat cancer. Given the increasing technology of the production of MTAs and their use in targeted therapies worldwide, their consumption market in Iran is expected to grow significantly
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
